Repurposed arthritis drug did not significantly improve severe COVID-19 pneumonia

In a study published online February 25, 2021 in The New England Journal of Medicine, a repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Results of the Phase III clinical trial, conducted by an international team led by senior author Atul Malhotra, MD, research chief of pulmonary, critical care and […]

Read more

Discovery of a new drug for diabetic retinopathy

A potentially effective treatment for diabetic retinopathy, a disease that swells and scars the retina, has been developed by an Université de Montréal scientist and investigator at Maisonneuve-Rosemont Hospital Research Centre (MRH-RC). Working with research scientist Pam Tsuruda of the San Francisco-based company UNITY Biotechnology, Przemyslaw (Mike) Sapieha published the results of the research project on mice Friday in the […]

Read more

Drink and drug risk is lower among optimistic pupils with ‘happy’ memories, says study

Teenagers with happy childhood memories are likely to drink less, take fewer drugs and enjoy learning, according to research published in the peer-reviewed journal Addiction Research & Theory. The findings, based on data from nearly 2,000 US high school students, show a link between how pupils feel about the past, present and future and their classroom behavior. This in turn […]

Read more

Potential combined drug therapy for lung cancer

Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly used for treating patients with NSCLC. It addresses a gene rearrangement known as ALK that occurs in 3 to 5% of NSCLC patients (alectinib belongs […]

Read more

The price of a drug should be based on its therapeutic benefits – not just what the market will bear

The U.S. pharmaceutical industry has innovated in response to the pandemic, providing not only vaccines but also therapies to treat people with COVID-19. But an outdated law designed to spur development of lifesaving drugs risks making new treatments—for COVID-19 as well as other diseases—unaffordable for many Americans. Many pharmaceutical companies rely on the Orphan Drug Act, which President Ronald Reagan […]

Read more

Thousands at risk of blindness set to benefit from a new eye drug

Thousands at risk of blindness set to benefit from a new drug that slows vision loss and can even improve sight Brolucizumab approved for patients with wet age-related macular deterioration The painless yet incurable eye disease is leading cause of blindness in over-55s New jab needs to be given only every 12 weeks rather than every single month Thousands of Britons […]

Read more

Blood pressure drug may be key to increasing lifespan, new study shows

Since time immemorial, people have been fascinated by ways to stop aging. Nearly every culture has stories to tell about people who lived for thousands of years, showing that extending lifespan has always been a deep desire across humanity. While modern medicine does not strive to find the fountain of youth, keen interest in promoting longevity has prompted research into […]

Read more

Study questions blood pressure drug guidance based on age and ethnicity

No evidence found to support differing advice according to age and ethnicity Current UK guidance on drug treatment for high blood pressure—which differs depending on a patient’s age and ethnicity—could be simplified in line with other international guidelines, suggests a study published by The BMJ. The results show similar reductions in blood pressure for three major drug types in people […]

Read more

FDA panel reviews 1st new Alzheimer’s drug in 2 decades

One of the biggest drug decisions in decades is looming as U.S. regulators consider whether to approve the first medicine that’s claimed to slow mental decline from Alzheimer’s disease, the most common form of dementia. A panel of outside experts meets Friday to advise the Food and Drug Administration on aducanumab, a drug from Cambridge, Massachusetts-based Biogen Inc. and Japan’s […]

Read more
1 2 3 7